Life Sciences Archive » December, 2016

Life Sciences - December, 2016

235 articles

• 6 Key Commercial Litigation Finance Trends For 2017
• 5 Ways To Fight Costlier Legal Malpractice Claims In 2017
• NJ Tax Judge Limits Access To Merck Property Sale Deal
• EU Unified Patent Court Will Proceed In 2017 — Now What?
• Mediating E-Discovery Disputes Can Save Time And Money
• Feds Push Through Record FCPA Week With Teva Case
• Supplement Co. Says Venable Can't Rep Foe In False Ad Row
• Insys Seeks Delay, Toss Of Investor Drug Plot Suit In Del.
• Doctor In Testosterone Gel MDL Must Reveal Drug Co. Deals
• Bio-Rad Can't Block Ex-GC's Evidence In Retaliation Trial
• Judge Backs Widow's Objection To GSK Trial Documents
• NJ Justices Won't Hear Ex-Merck Worker's Sex Bias Suit
• Ethicon Pushes Supreme Court To Hear AIA Process Case
• Schwarzenegger Supplement Maker, Rival Drop Ad Claim Suit
• Takeaways From China's Antitrust Case Against Medtronic
• New Obama Innovation Hub Targets Artificial Skin For Soldiers
• 5 Trends That Shaped The IPO Landscape In 2016
• Implied Preemption And Monograph Drugs: Part 2
• Teva Pharmaceutical To Pay $519M To Settle FCPA Charges
• Firms Fight For Equal Fees In $785M Pfizer FCA Deal
• Where 5 Top MDLs Stand At The End Of 2016
• Taro, Perrigo Hit With Price-Fixing Suit Over Skin Cream
• Bernstein Litowitz Ducks Subpoena In Insider Trading Row
• Celebrex Judge OKs $468M Settlement, $130M In Fees
• Warner Chilcott Urges Judge To Nix Asacol Antitrust Claims
• Implied Preemption And Monograph Drugs: Part 1
• Diet Pill Co., Snooki Ask To End Buyers' Zantrex False Ad Suit
• Breast Implant Maker To Pay $10.9M To End Securities Suit
• Bovine Sperm Co. Gets Genetics Patent Claim Nixed
• The Future Of Legal Marijuana: Post-Election Outlook
• State AGs May Turn Up Enforcement Under Trump
• Avoid Inadvertent Tipping This Holiday Season
• Building Momentum For The Pay Equity Movement In BigLaw
• Are You Prepared For A 'Post-Fact' Jury?
• Arnold & Porter, GE Counsel Hit With DQ Bid In IP Row
• Amphastar Urges 1st Circ. To Nix Rivals' Antitrust Immunity
• Allergan To Acquire Acelity-Owned LifeCell For $2.9B
• Calif. Attys' Press Statements Protected By Anti-SLAPP
• Tokai Hopes To Move $97M Suit Over IPO To Mass. Fed. Court
• 3rd Circ. Tosses Starch Co.'s Challenge To IP Rights Award
• $1B Verdict In J&J Hip Implant Bellwether Up For Judge's OK
• Stryker Must Face Sanctions For Frivolous Filing, Judge Told
• Pharmaceutical Formulations: Ready For Patenting?
• Teva Accuses Mylan, Others Of Infringing Copaxone Patent
• Deals Rumor Mill: Sanofi, Bright Food, Huawei Technologies
• US Solicitor Sides With Sandoz In Biosimilar Case
• Teva, Actavis, Sandoz Hit With Skin Cream Price-Fixing Suit
• BioZone Founder's Backbiting Breached Deal, Judge Told
• Judge Wrongly Limited Meningitis Outbreak Trial, Gov't Says
• Stryker Adds Patients To $1B Hip Implant Settlement
• Med Device Co. Can't Claim Extra Investment Grant
• Medical Laser Co. Lensar Hits Ch. 11 After IP Settlement
• 10th Circ. Won't Block Utah Contact Lens Pricing Law
• Shkreli's Ex-Atty Can't Get More Details On Fraud Charges
• Ex-Maquet Compliance Officer Files Whistleblower Suit
• EQT Inks €2.74B Sale Of BSN Medical
• Kite Hit With Suit After PTAB Upholds Cancer Therapy Patent
• Keeping Pro Se Litigants At Bay
• Kimberly-Clark Denied Bid For Delay In Gown Suit
• 21st Century Cures Act Benefits Biopharma Co. Data Use
• Ex-Cyberonics Sales Rep Can't Bring FCA Suit: 1st Circ.
• 11th Circ. Affirms Denial Of Fees In Legal Malpractice Row
• Drug Cos. Say Chicago's Opioid Claims Still Miss The Mark
• Pfizer And Subsidiaries Shake FCA Pain Patch Suit
• Rembrandt Urges High Court To Skip Expert Misconduct Case
• Reed Smith Widow Slams GSK's 'Mountain' Of Trial Exhibits
• 7th Circ. Sticks Surgical Tools Co. With Predecessor Tax Bill
• FDA Removes Chantix Warning About Suicidal Thoughts
• UK Antitrust Watchdog Accuses Actavis Of Excessive Pricing
• Mylan's Generic EpiPen Launches At Half The Price
• Health Hires: McCarter & English, Arent Fox, Nossaman
• Biotech Needn't Disclose Sponsored News, 11th Circ. Says
• Are Courts In The Discovery Driver's Seat?
• DaVita Gets Some Dialysis Death Claims Tossed
• Jury Finds Perrigo Infringed Pepcid Patent, Must Pay $10M
• 4 Key Takeaways From The DOJ's $4.7B FCA Haul
• Alere Granted Discovery After Abbott Seeks To Kill Merger
• Valeant Offering Needn't Meet Public Standards, SIFMA Says
• Covidien, Agency Urge Justices To Skip AIA Process Case
• Deals Rumor Mill: Verizon, Sanofi, Garena
• $38M FCA Payout Ends Kickback Suit Against Forest Labs
• FDA Hammers 2 More Drugmakers Over Bad Ads
• Masimo Says Rival's Blood Exam Patents Test Negative
• Idenix Wins $2.5B Verdict In Gilead Hep C Drug Patent Fight
• Takeda IP Suit Over Hikma Gout Flare Drug Is Reopened
• Amgen, Pfizer Sanction Bid Stirs Judge's Ire In Infection Row
• Pharmacy Execs Score Separate Trials Over Deadly Outbreak
• Lonza Snaps Up KKR-Backed Capsugel In $5.5B Deal
• Fujifilm To Expand Health Care Biz With $1.3B Wako Buy
• FDA Regulation Of Laboratory Developed Tests: A Long Saga
• Life Sciences MVP: Sullivan's Krishna Veeraraghavan
• 20 States Sue Generic-Drug Companies Over Collusion
• 6 Ways IP Enforcement Plan Impacts Public Health And Safety
• Endo's False Ad Claims Against Actavis Tossed For Good
• Life Sciences MVP: Paul Weiss' Catherine Nyarady
• Baxter Wins Bid To Keep Dechert Docs From Insurer
• Direct Buyers Push 1st Circ. To Rethink Nexium Suit
• FDA Scolds Celgene, Sanofi For Cluttered TV Ads
• Baxter, Hospira Fixed Saline Prices, Pa. Hospital Says
• NYC To Create $100M Life Sciences Campus
• 2nd Circ. Judge Worried Icahn Trade Tactic Reaps 'Zillions'
• Judge Wants More Info From Fresenius Dialysis Patients
• Alleged Health Fraud Ringleader Held After Making Threats
• FCA Crackdown Nets $4.7B In 2016, Capping Historic Run
• Colgate-Using Judge Can Stay On False Ad Suit, Co. Says
• Inciting Innovation In Drug And Medical Device Development
• Judge OKs Jury Trial In Ferring False Ad Row Over Drug
• DOJ Charges 2 Execs In Generic Drug Price-Fixing Plot
• The Outlook On Drug Pricing: At What Cost?
• Greatbatch Can't Hike Damages After Patent Win Against AVX
• Non-Residents' Plavix Row Belongs In Calif., High Court Told
• Anesthesia Firm Investor Says Board Has Entrenched Itself
• La. Tells 3rd Circ. It's Not Part Of GSK Antitrust Settlement
• Ex-InterMune Exec Says Salman Voids Insider Trading Loss
• Rules Of Civil Procedure Updates Affect E-Discovery
• Philly Judge Junks J&J Risperdal Case Midtrial
• CPSC Civil Penalties: Setting New Records In 2016
• The Path To The California Bench
• Indivior Wants States' Suboxone Product-Hop Claims Nixed
• OPINION: The ITC's Opportunity To Seize The Moment
• SEC Says Bio-Rad Wrong To Call Ex-GC's Work Privileged
• BigLaw Alums Q&A: Capital Appellate's Larry Ebner
• Life Sciences MVP: Latham & Watkins' John Manthei
• Buyers Want 1st Circ. To Rethink Nexium Pay-For-Delay Suit
• 3 Tips To Avoid Being On The Outs With In-House Counsel
• Staar Surgical Investors Seek Class Cert. In Stock-Drop Row
• GSK, Nev. Abused Fed. Drug Discount Program, 9th Circ. Told
• High Court Biosimilar Drama Intact After Amgen-Apotex Denial
• Kasowitz Can't Use FCA For Unlevied Fines: Chem Cos.
• Deals Rumor Mill: 21st Century Fox, Lonza, Sabeco
• Arthrex Wins $17M Verdict In Surgery Implant Patent Suit
• Bayer, Versant Invest $225M In Stem Cell Venture
• Facing $91M IP Judgment, Neovasc To Sell Facility
• Kansas Class To Lead Lanham Act Trial In Syngenta MDL
• Life Sciences MVP: Kirkland & Ellis' Jay Lefkowitz
• Hagens Berman Says Special Master Inquiry Risks Privilege
• Express Scripts Says Stockholder Suit Lacks Fraud Proof
• PTAB Agrees To Review Allergan Restasis Patents
• Women In Mesh MDL Must Show Safer Design Was Feasible
• Life Sciences MVP: White & Case's J. Mark Gidley
• Vitamin Co. Can't Shake 'Made In USA' Suit, Consumer Says
• JPML Centralizes J&J Invokana Unit Litigation In N.J.
• FTC Says Boehringer Should Cough Up Pay-For-Delay Docs
• Pharmacy Execs Want Separate Trials Over Deadly Outbreak
• Deals Rumor Mill: PPD, CCP, Time
• The Horrible Conflict Between Biology And Women Attorneys
• Boston Scientific Wages IP Suit Against Nevro's Pain Device
• Diet Pill Maker Seeks Sanctions For FTC Witness's Husband
• Sanofi Can't Enforce Deal It Broke In $20M Suit, Elorac Says
• How Latin America Is Stepping Up Anti-Corruption Efforts
• The Top Product Liability Cases Of 2016: Year-End Report
• FTC And Courts Remain Real Serious About Fake News Ads
• 3rd Circ. Won't Rethink Nixing Of Law Firm's Risperdal Suit
• Novartis Loses At BALCA In Case Over Exec. Director Job
• Ex-Insys Executives Charged In Painkiller Kickback Scheme
• Fed. Circ. Upholds Toss Of Plastic-Product Packaging IP
• Grifols Accused Of Off-Label Drug Uses In FCA Suit
• Hemispherex Investors Put Anti-Fatigue Drug Suit To Rest
• Atty DQ Sought In Medical Supplier Trademark Row
• Bristol-Myers Squibb To Pay $19.5M Over Abilify Marketing
• Lawyer EQ: Finding Success In Every Interaction
• FCA Decision Tracker: Continued Interpretations Of Escobar
• Inside The 2nd Circ. Ruling In Abbott V. Adelphia
• Managing Intergenerational Differences Within Your Law Firm
• Reliable Analysis Is Key To Addressing Ascertainability
• NY Firm, Ex-Client Ask 11th Circ. To Fix Jury's Errors
• Medical Group Pays $9.3M To Settle TCPA Junk Fax Claims
• Fed. Circ. Says PTAB Didn't Explain Itself In NuVasive Review
• GNC Agrees To Pay $2.3M Over Mislabeled Supplements
• Congress Passes Major Pharmaceutical Reform Bill
• The FTC's Overreaching Regulation Of Homeopathic Drugs
• Doc Says Bayer Axed Her For Backing Pregnant Worker
• Bayer Gets Win In Dentist's Antibiotic-Damage Suit
• Talking 'Bull': Episode 8, Too Perfect
• Colitis Drug Buyers Fight Doc Requests In Antitrust Row
• Pfizer Fined $106M Over Price Of Epilepsy Drug In UK
• House To Vote For Funding Bandage To Hold Gov't Until April
• Deals Rumor Mill: Bayer, Pandora, Montagu Private Equity
• Patients Urge 7th Circ. To Keep Eye Drop Class Cert.
• Philip Hirschkop: Quietly Making Noise For 50 Years
• Abbott Asks Chancery Court To Kill $5.8B Alere Buyout
• FDA Warning Wire: Agency Sour On Juice Health Claims
• Justices Wary Of Complicated Rule In Patent-Export Case
• Gilead Uses Merck As Shield In $2.5B Idenix Patent Fight
• Forest Blasts Attys' 'Shameful' Conduct In FCA Suit
• Congress Passes Health Care Access Data Bill
• Novo Nordisk Pledges To Limit Drug Price Increases
• NJ Justices Won't Review $11M J&J Pelvic Mesh Bellwether
• Supplement Buyer Stands Behind False Ad Accusations
• Medicines Co. Gets Fed. Circ. Grilling On Blood Thinner IP
• Vitamin Co. Says 'Made In USA' Cert. Bid Lacks Evidence
• Momenta Asks 1st Circ. To Affirm Enoxaparin Suit Immunity
• Idenix Seeks $2.5B In Gilead Hep C Drug Patent Dispute
• Promega IP Case May Portend More Liability For Exporting Cos.
• Apotex Can't Ditch Subpoena From Sandoz, Court Says
• Major Pharmaceutical Reform Bill Taken Up By Senate
• Watson Labs Urges Justices To Keep 'On Sale' Bar Intact
• New Atty's Scheduling Mixup Not Court's Problem, Judge Says
• Insurers Must Pay Counterclaims, Mass. High Court Told
• ITC To Investigate PacBio's DNA Sequencer Patent Claim
• Aegerion To Pay Investors $22M In Juxtapid Marketing Row
• Drug Cos. Urge High Court To Nix State Law Claims On Reglan
• Deals Rumor Mill: Sanofi, Northland Power, Sirius XM
• J&J Asks 1st Circ. To Halt Hip Implant FCA Suit
• Offshore Patent Transfer Payments Draw IRS, Court Scrutiny
• Cannabis Industry Faces Budding Product Liability Issues
• PTAB Rejects Dr. Reddy's Challenges To Suboxone Patents
• Stryker Asks 6th Circ. To Rethink $8.6M Coverage Loss
• Payor Swings Back At GSK Sanctions Bid In Avandia MDL
• The Causation Question Left Unanswered By Actavis
• Huge Verdicts Won't Spur Settlement Talks In J&J Hip MDL
• Allergan Strikes Deal With Zydus In Colitis Drug IP Suit
• 5th Circ. Reverses $340M Antitrust Ruling Against Syringe Co.
• Simpson Thacher Leads Teleflex $1B Vascular Solutions Deal
• J&J Faces Risperdal Claims For 6th Time In Philadelphia
• Insurer Must Pay $15M For Toxic Vitamin Class Settlement
• PTAB Rejection Of Microscope Device IP Upheld By Fed. Circ.
• Deals Rumor Mill: PAI Partners, Ladder Capital, Fitbit
• Mass. Appeals Court Nixes Drug Royalty Suit
• Eli Lilly Challenges Apotex's Proposed Cialis Generic
• Plaintiffs Seek Consolidation In Meningitis Outbreak Case
• 5 Insights From Airbus Group's Joshua Walker
• Safeway Must Face Inflated Drug Price Suit
• University Wants Unpaid Patent License Fees Suit Revived
• Rite Aid Can't Demand Union Remove Staff, Judge Says
• Allergan Sues Drugmakers Over Linzess Generics
• FDA Smacks Down Vanda's Bid To Block Fanapt Generics
• Attys Lose $35K Fee After 7th Circ. Orders New Analysis
• Experts Hampered In Depakote Birth Defect Trial, Mom Says
• CORRECTED: Novartis Knocks Colombia Over Leukemia Drug Price Control
• PTAB Finds Covidien Surgical Instrument Patent Invalid
• Fat-Freezing Licensee Says Spa Is Infringing
• 3rd J&J Hip Implant Bellwether Delivers $1B Verdict
• What's At Stake In High Court's Life Tech Patent Case
• Despite Momentum, Marijuana Remains Risky Business